Skip to Main Content

WASHINGTON — Unless Republicans abruptly change course in their plan to repeal and replace the Affordable Care Act, it appears the drug industry will dodge one of its most-feared bullets in health reform.

The House GOP plan that leaked last week did not include pharma-focused offsets — spending cuts or other cost savings — to pay for itself. Perhaps the biggest risk in this debate for drug makers, as STAT reported in December, had been the specter of any offsets targeting them.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!